- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05675410
- Original Trial
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Study Overview
Status
Intervention / Treatment
- Drug: Etoposide
- Biological: Nivolumab
- Other: Questionnaire Administration
- Procedure: Biospecimen Collection
- Drug: Cyclophosphamide
- Drug: Prednisone
- Drug: Vincristine Sulfate
- Drug: Dacarbazine
- Drug: Doxorubicin Hydrochloride
- Drug: Vinblastine Sulfate
- Drug: Brentuximab Vedotin
- Drug: Etoposide Phosphate
- Drug: Prednisolone
- Procedure: Computed Tomography
- Biological: Bleomycin Sulfate
- Other: Fludeoxyglucose F-18
- Procedure: Magnetic Resonance Imaging
- Procedure: Positron Emission Tomography
- Radiation: Involved-site Radiation Therapy
- Drug: Procarbazine Hydrochloride
Detailed Description
PRIMARY OBJECTIVES:
I. To compare the progression-free survival (PFS) of a standard chemotherapy approach versus an immunotherapy (IO) approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage classic Hodgkin lymphoma (cHL) who have a rapid early response (RER) as determined by position emission tomography post cycle 2 (PET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
II. To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.
SECONDARY OBJECTIVES:
I. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a RER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
II. To evaluate the overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a SER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
III. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients.
IV. To evaluate in patients with newly diagnosed early stage cHL the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in the overall cohort, in the favorable risk cohort, and in the unfavorable risk cohort.
V. To evaluate the event-free survival (EFS) at 12 years of patients undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab).
VI. To compare the physician-reported treatment-related adverse event (AE) rates between a standard chemotherapy approach and an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL.
VII. To compare patient-reported adverse events using pediatric and adult versions of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), stratified by age groups, therapeutic arms, and receipt of radiation therapy (RT) over time.
VIII. To evaluate changes in patient-reported fatigue, cognitive functioning, and health-related quality of life (HRQoL), e.g., emotional, physical, and role functioning, by treatment arm, using validated adult and pediatric measurement systems.
IX. To evaluate self-reported late morbidities (e.g., cardiovascular, pulmonary and endocrine) over time for children, adolescents and adults undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab) with and without RT using measures from the St. Jude Lifetime Cohort Study (SJLIFE).
X. To evaluate fludeoxyglucose F-18 (FDG)-position emission tomography (PET) measurements of metabolic tumor burden (MTV and total lesion glycolysis [TLG]) at PET at baseline (PET1) as a predictive marker of PFS.
XI. To evaluate the associations between race/ethnicity and key outcomes including early response to therapy, PFS and OS.
EXPLORATORY OBJECTIVES:
I. To evaluate the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL across different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years).
II. To bank specimens for future correlative studies. III. To assess concordance and discordance of rapid central review and local institutional review of FDG PET 5-point score (5-PS; previously referred to as Deauville score) at baseline PET1, interim PET2 and end of systemic therapy PET-end of systemic therapy (EST) SER.
IV. To assess the association between PFS and the quantitative FDG-PET/computed tomography (CT) parameters (PET MTV, TLG, delta-standardized uptake value [SUV] and PET SUV-based quantitative surrogates [qPET] of visual qualitative 5-PS) on measurements by automated measurements using convolutional neural networks (CNNs) through artificial-intelligence (AI) machine learning in the entire population.
V. To assess the agreement between quantitative FDG-PET/CT parameters obtained using AI and those based on measurements by a trained imaging physician.
VI. To compare patient-reported adverse events (via pediatric [Ped]-PRO-CTCAE and PRO-CTCAE) to provider adverse event reporting.
VII. To evaluate the association between self-reported race/ethnicity and social determinants of health.
VIII. To evaluate the associations between race/ethnicity and post-progression/post-relapse overall survival.
IX. To evaluate the completion rates of PRO and health-related quality of life (HRQoL) contact forms at 1 year off treatment for the first 450 eligible patients.
X. To collect contact information from participants for future re-contact.
OUTLINE: Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride intravenously [IV] over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or magnetic resonance imaging (MRI) and are identified as RER or SER.
Patients with a favorable risk status and RER are randomized to Arm A or Arm B. Patients with a favorable risk status and SER are randomized to Arm C or Arm D. Patients with an unfavorable risk status and RER are randomized to Arm E or Arm F. Patients with an unfavorable risk status and SER are randomized to Arm G or Arm H.
ARM A (RER, FAVORABLE): Patients receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM B (RER, FAVORABLE): Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM C (SER, FAVORABLE): Patients receive either the eBEACOPP regimen (doxorubicin hydrochloride IV over 3-15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone orally [PO] twice daily [BID] on days 1-14, procarbazine hydrochloride PO on days 1-7, bleomycin sulfate IV over at least 10 minutes on day 8, and vincristine sulfate IV on day 8 of each cycle) or the eBPDac regimen (doxorubicin hydrochloride IV 3-15 minutes on day 1, cyclophosphamide IV 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone PO BID on days 1-14, dacarbazine IV over 15-60 minutes on days 2 & 3, bleomycin sulfate IV over at least 10 minutes on day 4, 5, 6, 7, or 8, vincristine sulfate IV on day 4, 5, 6, 7, or 8 of each cycle). Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Subsequently, patients undergo ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM D (SER, FAVORABLE): Patients receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM E (RER, UNFAVORABLE): Patients receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM F (RER, UNFAVORABLE): Patients receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.
ARM G (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm C.
ARM H (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm D.
After completion of study treatment, patients are followed up every 3 months for the first year, then every 6 months for the second and third year, then annually until 12 years from date of registration.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Québec, Canada, G1V 4G2
- Recruiting
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Principal Investigator:
- Bruno Michon
-
Contact:
- Site Public Contact
- Phone Number: 418-525-4444
- Email: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Recruiting
- Alberta Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 403-220-6898
- Email: research4kids@ucalgary.ca
-
Principal Investigator:
- Victor A. Lewis
-
Edmonton, Alberta, Canada, T6G 2B7
- Recruiting
- University of Alberta Hospital
-
Contact:
- Site Public Contact
- Phone Number: 780-407-8798
- Email: pedsoncologyresearch@ahs.ca
-
Principal Investigator:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Recruiting
- British Columbia Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 6477 604-875-2345
-
Principal Investigator:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- Recruiting
- CancerCare Manitoba
-
Contact:
- Site Public Contact
- Phone Number: 866-561-1026
- Email: ctu_web@cancercare.mb.ca
-
Principal Investigator:
- Stephanie M. Villeneuve
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- Recruiting
- IWK Health Centre
-
Contact:
- Site Public Contact
- Phone Number: 902-470-8520
- Email: Research@iwk.nshealth.ca
-
Principal Investigator:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Recruiting
- McMaster Children's Hospital at Hamilton Health Sciences
-
Contact:
- Site Public Contact
- Phone Number: 905-521-2100
-
Principal Investigator:
- Uma H. Athale
-
London, Ontario, Canada, N6A 5W9
- Recruiting
- Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 519-685-8306
-
Principal Investigator:
- Shayna M. Zelcer
-
Ottawa, Ontario, Canada, K1H 8L1
- Recruiting
- Children's Hospital of Eastern Ontario
-
Contact:
- Site Public Contact
- Phone Number: 613-737-7600
-
Principal Investigator:
- Donna L. Johnston
-
Toronto, Ontario, Canada, M5G 1X8
- Recruiting
- Hospital for Sick Children
-
Contact:
- Site Public Contact
- Phone Number: 416-813-7654
- Email: ask.CRS@sickkids.ca
-
Principal Investigator:
- Angela S. Punnett
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Recruiting
- The Montreal Children's Hospital of the MUHC
-
Contact:
- Site Public Contact
- Phone Number: 514-412-4445
- Email: info@thechildren.com
-
Principal Investigator:
- Stephanie Mourad
-
Montreal, Quebec, Canada, H3T 1C5
- Recruiting
- Centre Hospitalier Universitaire Sainte-Justine
-
Principal Investigator:
- Monia Marzouki
-
Contact:
- Site Public Contact
- Phone Number: 514-345-4931
- Email: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Recruiting
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Contact:
- Site Public Contact
- Phone Number: 819-820-6480
- Email: crcinformation.chus@ssss.gouv.qc.ca
-
Principal Investigator:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Recruiting
- Jim Pattison Children's Hospital
-
Principal Investigator:
- Kathleen Felton
-
Contact:
- Site Public Contact
- Phone Number: 306-655-3544
- Email: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Recruiting
- University Pediatric Hospital
-
Contact:
- Site Public Contact
- Phone Number: 787-474-0333
-
Principal Investigator:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- Children's Hospital of Alabama
-
Principal Investigator:
- Ana C. Xavier
-
Contact:
- Site Public Contact
- Phone Number: 205-638-9285
- Email: oncologyresearch@peds.uab.edu
-
Mobile, Alabama, United States, 36604
- Recruiting
- USA Health Strada Patient Care Center
-
Contact:
- Site Public Contact
- Phone Number: 800-388-8721
-
Principal Investigator:
- Hamayun Imran
-
-
Alaska
-
Anchorage, Alaska, United States, 99508
- Recruiting
- Providence Alaska Medical Center
-
Principal Investigator:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Phone Number: 907-212-6871
- Email: AKPAMC.OncologyResearchSupport@providence.org
-
-
Arizona
-
Goodyear, Arizona, United States, 85338
- Recruiting
- CTCA at Western Regional Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 623-207-3000
-
Principal Investigator:
- Jeffrey R. Schriber
-
Mesa, Arizona, United States, 85202
- Recruiting
- Banner Children's at Desert
-
Contact:
- Site Public Contact
- Phone Number: 480-412-3100
-
Principal Investigator:
- Joseph C. Torkildson
-
Phoenix, Arizona, United States, 85016
- Recruiting
- Phoenix Childrens Hospital
-
Contact:
- Site Public Contact
- Phone Number: 602-546-0920
-
Principal Investigator:
- Alexandra M. Walsh
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202-3591
- Recruiting
- Arkansas Children's Hospital
-
Principal Investigator:
- Michael W. Bishop
-
Contact:
- Site Public Contact
- Phone Number: 501-364-7373
-
-
California
-
Carmichael, California, United States, 95608
- Recruiting
- Mercy San Juan Medical Center
-
Principal Investigator:
- Shahzad Siddique
-
Contact:
- Site Public Contact
- Phone Number: 720-874-1881
- Email: ResearchInstituteInquiries@CommonSpirit.org
-
Carmichael, California, United States, 95608
- Recruiting
- Mercy Cancer Center - Carmichael
-
Principal Investigator:
- Shahzad Siddique
-
Contact:
- Site Public Contact
- Phone Number: 720-874-1881
- Email: ResearchInstituteInquiries@CommonSpirit.org
-
Corona, California, United States, 92882
- Recruiting
- City of Hope Corona
-
Principal Investigator:
- Alex F. Herrera
-
Contact:
- Site Public Contact
- Phone Number: 626-256-4673
- Email: becomingapatient@coh.org
-
Costa Mesa, California, United States, 92627
- Recruiting
- UC Irvine Health Cancer Center-Newport
-
Contact:
- Site Public Contact
- Phone Number: 877-827-8839
-
Principal Investigator:
- Nicole Foley
-
Downey, California, United States, 90242
- Recruiting
- Kaiser Permanente Downey Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 626-564-3455
-
Principal Investigator:
- Robert M. Cooper
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-826-4673
- Email: becomingapatient@coh.org
-
Principal Investigator:
- Alex F. Herrera
-
Dublin, California, United States, 94568
- Recruiting
- Kaiser Permanente Dublin
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
-
Principal Investigator:
- Sachdev P. Thomas
-
Elk Grove, California, United States, 95758
- Recruiting
- Mercy Cancer Center - Elk Grove
-
Principal Investigator:
- Shahzad Siddique
-
Contact:
- Site Public Contact
- Phone Number: 720-874-1881
- Email: ResearchInstituteInquiries@CommonSpirit.org
-
Fremont, California, United States, 94538
- Recruiting
- Kaiser Permanente-Fremont
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Fresno, California, United States, 93720
- Recruiting
- Kaiser Permanente-Fresno
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Fresno, California, United States, 93720
- Suspended
- Kaiser Permanente Fresno Orchard Plaza
-
Huntington Beach, California, United States, 92648
- Recruiting
- City of Hope Seacliff
-
Principal Investigator:
- Alex F. Herrera
-
Contact:
- Site Public Contact
- Phone Number: 626-256-4673
-
Irvine, California, United States, 92618
- Recruiting
- City of Hope at Irvine Lennar
-
Contact:
- Site Public Contact
- Phone Number: 877-467-3411
-
Principal Investigator:
- Alex F. Herrera
-
Irvine, California, United States, 92612
- Recruiting
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Contact:
- Site Public Contact
- Phone Number: 877-827-8839
- Email: ucstudy@uci.edu
-
Principal Investigator:
- Nicole Foley
-
Lancaster, California, United States, 93534
- Recruiting
- City of Hope Antelope Valley
-
Contact:
- Site Public Contact
- Phone Number: 800-826-4673
- Email: becomingapatient@coh.org
-
Principal Investigator:
- Alex F. Herrera
-
Loma Linda, California, United States, 92354
- Recruiting
- Loma Linda University Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 909-558-4050
-
Principal Investigator:
- Albert Kheradpour
-
Long Beach, California, United States, 90806
- Recruiting
- Miller Children's and Women's Hospital Long Beach
-
Contact:
- Site Public Contact
- Phone Number: 562-933-5600
-
Principal Investigator:
- Jacqueline N. Casillas
-
Long Beach, California, United States, 90813
- Recruiting
- City of Hope at Long Beach Elm
-
Contact:
- Site Public Contact
- Phone Number: 877-467-3411
-
Principal Investigator:
- Alex F. Herrera
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hospital Los Angeles
-
Contact:
- Site Public Contact
- Phone Number: 323-361-4110
-
Principal Investigator:
- Andrew Doan
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center
-
Principal Investigator:
- Nicole M. Baca
-
Contact:
- Site Public Contact
- Phone Number: 310-423-2133
- Email: Cancer.trial.info@cshs.org
-
Madera, California, United States, 93636
- Recruiting
- Valley Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 559-353-3000
- Email: Research@valleychildrens.org
-
Principal Investigator:
- Ruetima Titapiwatanakun
-
Modesto, California, United States, 95356
- Recruiting
- Kaiser Permanente-Modesto
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Modesto, California, United States, 95356
- Suspended
- Kaiser Permanente- Modesto MOB II
-
Newport Beach, California, United States, 92660
- Recruiting
- City of Hope Newport Beach
-
Contact:
- Site Public Contact
- Phone Number: 877-467-3411
-
Principal Investigator:
- Alex F. Herrera
-
Oakland, California, United States, 94611
- Recruiting
- Kaiser Permanente-Oakland
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Aarati V. Rao
-
Orange, California, United States, 92868
- Recruiting
- Children's Hospital of Orange County
-
Contact:
- Site Public Contact
- Phone Number: 714-509-8646
- Email: oncresearch@choc.org
-
Principal Investigator:
- Elyssa M. Rubin
-
Orange, California, United States, 92868
- Recruiting
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 877-827-8839
- Email: ucstudy@uci.edu
-
Principal Investigator:
- Nicole Foley
-
Rocklin, California, United States, 95765
- Recruiting
- Mercy Cancer Center - Rocklin
-
Principal Investigator:
- Shahzad Siddique
-
Contact:
- Site Public Contact
- Phone Number: 720-874-1881
- Email: ResearchInstituteInquiries@CommonSpirit.org
-
Sacramento, California, United States, 95814
- Recruiting
- Kaiser Permanente Downtown Commons
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Sacramento, California, United States, 95816
- Recruiting
- Sutter Medical Center Sacramento
-
Contact:
- Site Public Contact
- Email: clinicalresearch@sutterhealth.org
-
Principal Investigator:
- Sandra Baril
-
Sacramento, California, United States, 95823
- Recruiting
- Kaiser Permanente-South Sacramento
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Sacramento, California, United States, 95816
- Recruiting
- Mercy Cancer Center - Sacramento
-
Principal Investigator:
- Shahzad Siddique
-
Contact:
- Site Public Contact
- Phone Number: 720-874-1881
- Email: ResearchInstituteInquiries@CommonSpirit.org
-
San Diego, California, United States, 92123
- Recruiting
- Rady Children's Hospital - San Diego
-
Contact:
- Site Public Contact
- Phone Number: 858-966-5934
-
Principal Investigator:
- William D. Roberts
-
San Diego, California, United States, 92134
- Recruiting
- Naval Medical Center -San Diego
-
Contact:
- Site Public Contact
- Phone Number: 619-532-8712
-
Principal Investigator:
- Yoko T. Udaka
-
San Francisco, California, United States, 94115
- Recruiting
- Kaiser Permanente-San Francisco
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
San Jose, California, United States, 95119
- Recruiting
- Kaiser Permanente-Santa Teresa-San Jose
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
San Leandro, California, United States, 94577
- Recruiting
- Kaiser Permanente San Leandro
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
San Rafael, California, United States, 94903
- Recruiting
- Kaiser San Rafael-Gallinas
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Santa Barbara, California, United States, 93102
- Recruiting
- Santa Barbara Cottage Hospital
-
Contact:
- Site Public Contact
- Phone Number: 805-682-7300
-
Principal Investigator:
- Shivani Upadhyay
-
Santa Rosa, California, United States, 95403
- Recruiting
- Kaiser Permanente-Santa Rosa
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
South Pasadena, California, United States, 91030
- Recruiting
- City of Hope South Pasadena
-
Contact:
- Site Public Contact
- Phone Number: 800-826-4673
- Email: becomingapatient@coh.org
-
Principal Investigator:
- Alex F. Herrera
-
South San Francisco, California, United States, 94080
- Recruiting
- Kaiser Permanente-South San Francisco
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Torrance, California, United States, 90503
- Recruiting
- City of Hope South Bay
-
Contact:
- Site Public Contact
- Phone Number: 877-467-3411
-
Principal Investigator:
- Alex F. Herrera
-
Upland, California, United States, 91786
- Recruiting
- City of Hope Upland
-
Contact:
- Site Public Contact
- Phone Number: 800-826-4673
- Email: becomingapatient@coh.org
-
Principal Investigator:
- Alex F. Herrera
-
Vallejo, California, United States, 94589
- Recruiting
- Kaiser Permanente-Vallejo
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Walnut Creek, California, United States, 94596
- Recruiting
- Kaiser Permanente-Walnut Creek
-
Contact:
- Site Public Contact
- Phone Number: 877-642-4691
- Email: Kpoct@kp.org
-
Principal Investigator:
- Sachdev P. Thomas
-
Woodland, California, United States, 95695
- Recruiting
- Woodland Memorial Hospital
-
Principal Investigator:
- Shahzad Siddique
-
Contact:
- Site Public Contact
- Phone Number: 720-874-1881
- Email: ResearchInstituteInquiries@CommonSpirit.org
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
Contact:
- Site Public Contact
- Phone Number: 303-764-5056
- Email: josh.b.gordon@nsmtp.kp.org
-
Principal Investigator:
- Kelly W. Maloney
-
Aurora, Colorado, United States, 80045
- Recruiting
- UCHealth University of Colorado Hospital
-
Principal Investigator:
- Sarah Milgrom
-
Contact:
- Site Public Contact
- Phone Number: 720-848-0650
-
Colorado Springs, Colorado, United States, 80909
- Recruiting
- UCHealth Memorial Hospital Central
-
Principal Investigator:
- Sarah Milgrom
-
Contact:
- Site Public Contact
- Phone Number: 719-365-2406
-
Colorado Springs, Colorado, United States, 80920
- Recruiting
- Memorial Hospital North
-
Principal Investigator:
- Sarah Milgrom
-
Contact:
- Site Public Contact
- Phone Number: 719-364-6700
-
Denver, Colorado, United States, 80218
- Recruiting
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 303-832-2344
- Email: PSGResearchSharedMailbox@HCAHealthcare.com
-
Principal Investigator:
- Florence Choo
-
Fort Collins, Colorado, United States, 80524
- Recruiting
- Poudre Valley Hospital
-
Principal Investigator:
- Sarah Milgrom
-
Contact:
- Site Public Contact
- Phone Number: 970-297-6150
-
Fort Collins, Colorado, United States, 80528
- Recruiting
- Cancer Care and Hematology-Fort Collins
-
Principal Investigator:
- Sarah Milgrom
-
Contact:
- Site Public Contact
- Phone Number: 888-823-5923
- Email: ctsucontact@westat.com
-
Greeley, Colorado, United States, 80631
- Recruiting
- UCHealth Greeley Hospital
-
Principal Investigator:
- Sarah Milgrom
-
Contact:
- Site Public Contact
- Phone Number: 888-823-5923
- Email: ctsucontact@westat.com
-
Loveland, Colorado, United States, 80538
- Recruiting
- Medical Center of the Rockies
-
Principal Investigator:
- Sarah Milgrom
-
Contact:
- Site Public Contact
- Phone Number: 970-203-7083
-
-
Connecticut
-
Derby, Connecticut, United States, 06418
- Recruiting
- Smilow Cancer Hospital-Derby Care Center
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Fairfield, Connecticut, United States, 06824
- Recruiting
- Smilow Cancer Hospital Care Center-Fairfield
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Glastonbury, Connecticut, United States, 06033
- Recruiting
- Smilow Cancer Hospital Care Center at Glastonbury
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Greenwich, Connecticut, United States, 06830
- Recruiting
- Smilow Cancer Hospital Care Center at Greenwich
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Guilford, Connecticut, United States, 06437
- Recruiting
- Smilow Cancer Hospital Care Center - Guilford
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Hartford, Connecticut, United States, 06106
- Recruiting
- Connecticut Children's Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 860-545-9981
-
Principal Investigator:
- Michael S. Isakoff
-
Hartford, Connecticut, United States, 06105
- Recruiting
- Smilow Cancer Hospital Care Center at Saint Francis
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
New Haven, Connecticut, United States, 06520
- Recruiting
- Yale University
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
North Haven, Connecticut, United States, 06473
- Recruiting
- Yale-New Haven Hospital North Haven Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Stamford, Connecticut, United States, 06902
- Recruiting
- Smilow Cancer Hospital Care Center at Long Ridge
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Torrington, Connecticut, United States, 06790
- Recruiting
- Smilow Cancer Hospital-Torrington Care Center
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Trumbull, Connecticut, United States, 06611
- Recruiting
- Smilow Cancer Hospital Care Center-Trumbull
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Waterbury, Connecticut, United States, 06708
- Recruiting
- Smilow Cancer Hospital-Waterbury Care Center
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
Waterford, Connecticut, United States, 06385
- Recruiting
- Smilow Cancer Hospital Care Center - Waterford
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, United States, 19803
- Recruiting
- Alfred I duPont Hospital for Children
-
Contact:
- Site Public Contact
- Phone Number: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Principal Investigator:
- Vibhuti Agarwal
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20010
- Recruiting
- Children's National Medical Center
-
Principal Investigator:
- Jeffrey S. Dome
-
Contact:
- Site Public Contact
- Phone Number: 202-476-2800
- Email: OncCRC_OnCall@childrensnational.org
-
Washington D.C., District of Columbia, United States, 20007
- Recruiting
- MedStar Georgetown University Hospital
-
Contact:
- Site Public Contact
- Phone Number: 202-444-2223
-
Principal Investigator:
- Caileigh Pudela
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
- Recruiting
- Broward Health Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Principal Investigator:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, United States, 33908
- Recruiting
- Golisano Children's Hospital of Southwest Florida
-
Contact:
- Site Public Contact
- Phone Number: 239-343-5333
- Email: molly.arnstrom@leehealth.org
-
Principal Investigator:
- Emad K. Salman
-
Gainesville, Florida, United States, 32610
- Recruiting
- UF Health Cancer Institute - Gainesville
-
Principal Investigator:
- Brian Stover
-
Contact:
- Site Public Contact
- Phone Number: 352-273-8010
-
Hollywood, Florida, United States, 33021
- Recruiting
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 954-265-1847
- Email: OHR@mhs.net
-
Principal Investigator:
- Iftikhar Hanif
-
Jacksonville, Florida, United States, 32207
- Recruiting
- Nemours Children's Clinic-Jacksonville
-
Contact:
- Site Public Contact
- Phone Number: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Principal Investigator:
- Vibhuti Agarwal
-
Jacksonville, Florida, United States, 32224-9980
- Recruiting
- Mayo Clinic in Florida
-
Principal Investigator:
- Mira Kohorst
-
Contact:
- Site Public Contact
- Phone Number: 855-776-0015
-
Miami, Florida, United States, 33155
- Recruiting
- Nicklaus Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 888-624-2778
-
Principal Investigator:
- Maggie E. Fader
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 305-243-2647
-
Principal Investigator:
- Warren Alperstein
-
Miami Beach, Florida, United States, 33140
- Recruiting
- Mount Sinai Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 305-674-2625
- Email: Yvonne.Enriquez@msmc.com
-
Principal Investigator:
- Jacqueline C. Barrientos
-
Orlando, Florida, United States, 32806
- Recruiting
- Arnold Palmer Hospital for Children
-
Contact:
- Site Public Contact
- Phone Number: 321-841-5357
- Email: Jennifer.spinelli@orlandohealth.com
-
Principal Investigator:
- Zhongbo Hu
-
Orlando, Florida, United States, 32827
- Recruiting
- Nemours Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 302-651-5572
- Email: Allison.bruce@nemours.org
-
Principal Investigator:
- Vibhuti Agarwal
-
Orlando, Florida, United States, 32803
- Recruiting
- AdventHealth Orlando
-
Contact:
- Site Public Contact
- Phone Number: 407-303-2090
- Email: FH.Cancer.Research@flhosp.org
-
Principal Investigator:
- Fouad M. Hajjar
-
Pensacola, Florida, United States, 32504
- Suspended
- Sacred Heart Hospital
-
Pensacola, Florida, United States, 32504
- Recruiting
- Nemours Children's Clinic - Pensacola
-
Contact:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Principal Investigator:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, United States, 33701
- Recruiting
- Johns Hopkins All Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 727-767-4784
- Email: Ashley.Repp@jhmi.edu
-
Principal Investigator:
- Jennifer B. Dean
-
Tampa, Florida, United States, 33606
- Recruiting
- Tampa General Hospital
-
Contact:
- Site Public Contact
- Phone Number: 813-844-7829
- Email: syapchanyk@tgh.org
-
Principal Investigator:
- Andrew J. Galligan
-
Tampa, Florida, United States, 33607
- Recruiting
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Contact:
- Site Public Contact
- Phone Number: 813-357-0849
- Email: jennifer.manns@baycare.org
-
Principal Investigator:
- Don E. Eslin
-
West Palm Beach, Florida, United States, 33407
- Recruiting
- Saint Mary's Medical Center
-
Principal Investigator:
- Matthew D. Ramirez
-
Contact:
- Site Public Contact
- Phone Number: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University Hospital/Winship Cancer Institute
-
Contact:
- Site Public Contact
- Phone Number: 404-778-1868
-
Principal Investigator:
- Pamela B. Allen
-
Atlanta, Georgia, United States, 30303
- Recruiting
- Grady Health System
-
Contact:
- Site Public Contact
- Phone Number: 404-778-1868
-
Principal Investigator:
- Pamela B. Allen
-
Atlanta, Georgia, United States, 30308
- Recruiting
- Emory University Hospital Midtown
-
Contact:
- Site Public Contact
- Phone Number: 888-946-7447
-
Principal Investigator:
- Pamela B. Allen
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Emory Saint Joseph's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 404-851-7115
-
Principal Investigator:
- Pamela B. Allen
-
Atlanta, Georgia, United States, 30308
- Recruiting
- Emory Proton Therapy Center
-
Contact:
- Site Public Contact
- Phone Number: 404-251-2854
- Email: allyson.anderson@emory.edu
-
Principal Investigator:
- Pamela B. Allen
-
Atlanta, Georgia, United States, 30329
- Recruiting
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Principal Investigator:
- Diana Fridlyand
-
Contact:
- Site Public Contact
- Phone Number: 404-785-0232
- Email: Olivia.Floyd@choa.org
-
Augusta, Georgia, United States, 30912
- Recruiting
- Augusta University Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 706-721-2388
- Email: ga_cares@augusta.edu
-
Principal Investigator:
- Colleen H. McDonough
-
Macon, Georgia, United States, 31201
- Recruiting
- Atrium Health Navicent
-
Principal Investigator:
- Sushmita Nair
-
Contact:
- Site Public Contact
- Phone Number: 478-633-2152
- Email: andrew.weatherall@atriumhealth.org
-
Savannah, Georgia, United States, 31404
- Recruiting
- Memorial Health University Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 912-350-7887
- Email: Lorraine.OHara@hcahealthcare.com
-
Principal Investigator:
- Andrew L. Pendleton
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96826
- Recruiting
- Kapiolani Medical Center for Women and Children
-
Contact:
- Site Public Contact
- Phone Number: 808-983-6090
-
Principal Investigator:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, United States, 83712
- Recruiting
- Saint Luke's Cancer Institute - Boise
-
Principal Investigator:
- Martha M. Pacheco
-
Contact:
- Site Public Contact
- Phone Number: 208-381-2774
- Email: eslinget@slhs.org
-
Boise, Idaho, United States, 83706
- Recruiting
- Saint Alphonsus Cancer Care Center-Boise
-
Contact:
- Site Public Contact
- Phone Number: 734-712-3671
- Email: stephanie.couch@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Caldwell, Idaho, United States, 83605
- Recruiting
- Saint Alphonsus Cancer Care Center-Caldwell
-
Contact:
- Site Public Contact
- Phone Number: 734-712-3671
- Email: stephanie.couch@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Fruitland, Idaho, United States, 83619
- Recruiting
- Saint Luke's Cancer Institute - Fruitland
-
Principal Investigator:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Phone Number: 208-381-2774
- Email: eslinget@slhs.org
-
Meridian, Idaho, United States, 83642
- Recruiting
- Idaho Urologic Institute-Meridian
-
Contact:
- Site Public Contact
- Phone Number: 734-712-3671
- Email: stephanie.couch@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Meridian, Idaho, United States, 83642
- Recruiting
- Saint Luke's Cancer Institute - Meridian
-
Principal Investigator:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Phone Number: 208-381-2774
- Email: eslinget@slhs.org
-
Nampa, Idaho, United States, 83687
- Recruiting
- Saint Luke's Cancer Institute - Nampa
-
Principal Investigator:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Phone Number: 208-381-2774
- Email: eslinget@slhs.org
-
Nampa, Idaho, United States, 83687
- Recruiting
- Saint Alphonsus Cancer Care Center-Nampa
-
Contact:
- Site Public Contact
- Phone Number: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Twin Falls, Idaho, United States, 83301
- Recruiting
- Saint Luke's Cancer Institute - Twin Falls
-
Principal Investigator:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Phone Number: 208-381-2774
- Email: eslinget@slhs.org
-
-
Illinois
-
Aurora, Illinois, United States, 60504
- Recruiting
- Rush-Copley Medical Center
-
Principal Investigator:
- Priyank P. Patel
-
Contact:
- Site Public Contact
- Phone Number: 630-978-6212
- Email: RCMC_Cancer_Research@rush.edu
-
Barrington, Illinois, United States, 60010
- Recruiting
- Advocate Good Shepherd Hospital
-
Contact:
- Site Public Contact
- Phone Number: 847-842-4847
-
Principal Investigator:
- Rebecca E. McFall
-
Chicago, Illinois, United States, 60611
- Recruiting
- Lurie Children's Hospital-Chicago
-
Contact:
- Site Public Contact
- Phone Number: 773-880-4562
-
Principal Investigator:
- Joanna L. Weinstein
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 773-702-8222
- Email: cancerclinicaltrials@bsd.uchicago.edu
-
Principal Investigator:
- Perry C. Morocco
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Principal Investigator:
- Jane N. Winter
-
Contact:
- Site Public Contact
- Phone Number: 312-695-1301
- Email: cancer@northwestern.edu
-
Chicago, Illinois, United States, 60612
- Recruiting
- University of Illinois
-
Contact:
- Site Public Contact
- Phone Number: 312-355-3046
-
Principal Investigator:
- Dipti S. Dighe
-
Chicago, Illinois, United States, 60657
- Recruiting
- Advocate Illinois Masonic Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 773-296-5360
-
Principal Investigator:
- Rebecca E. McFall
-
Chicago, Illinois, United States, 60608
- Recruiting
- Mount Sinai Hospital Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 773-257-5960
- Email: suhi@sinai.org
-
Principal Investigator:
- Pam G. Khosla
-
Chicago, Illinois, United States, 60625
- Recruiting
- Swedish Covenant Hospital
-
Contact:
- Site Public Contact
- Phone Number: 773-878-8200
-
Principal Investigator:
- Robert M. Eisner
-
Crystal Lake, Illinois, United States, 60014
- Recruiting
- AMG Crystal Lake - Oncology
-
Contact:
- Site Public Contact
- Phone Number: 630-929-6129
- Email: advocateresearch@advocate.com
-
Principal Investigator:
- Rebecca E. McFall
-
Danville, Illinois, United States, 61832
- Recruiting
- Carle at The Riverfront
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Priyank P. Patel
-
DeKalb, Illinois, United States, 60115
- Recruiting
- Northwestern Medicine Cancer Center Kishwaukee
-
Principal Investigator:
- Jane N. Winter
-
Contact:
- Site Public Contact
- Phone Number: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Decatur, Illinois, United States, 62526
- Recruiting
- Decatur Memorial Hospital
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Downers Grove, Illinois, United States, 60515
- Recruiting
- Advocate Good Samaritan Hospital
-
Contact:
- Site Public Contact
- Phone Number: 630-275-1270
- Email: Barbara.barhamand@advocatehealth.com
-
Principal Investigator:
- Rebecca E. McFall
-
Effingham, Illinois, United States, 62401
- Recruiting
- Carle Physician Group-Effingham
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Priyank P. Patel
-
Effingham, Illinois, United States, 62401
- Recruiting
- Crossroads Cancer Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, United States, 60123
- Recruiting
- Advocate Sherman Hospital
-
Contact:
- Site Public Contact
- Phone Number: 847-429-2907
-
Principal Investigator:
- Rebecca E. McFall
-
Elmhurst, Illinois, United States, 60126
- Recruiting
- Elmhurst Memorial Hospital
-
Principal Investigator:
- Joseph Heng
-
Contact:
- Site Public Contact
- Phone Number: 630-758-5460
- Email: Jrohde@emhc.org
-
Evanston, Illinois, United States, 60201
- Recruiting
- NorthShore University HealthSystem-Evanston Hospital
-
Contact:
- Site Public Contact
- Phone Number: 847-570-2109
-
Principal Investigator:
- Robert M. Eisner
-
Geneva, Illinois, United States, 60134
- Recruiting
- Northwestern Medicine Cancer Center Delnor
-
Principal Investigator:
- Jane N. Winter
-
Contact:
- Site Public Contact
- Phone Number: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Glenview, Illinois, United States, 60026
- Recruiting
- NorthShore University HealthSystem-Glenbrook Hospital
-
Contact:
- Site Public Contact
- Phone Number: 847-570-2109
-
Principal Investigator:
- Robert M. Eisner
-
Glenview, Illinois, United States, 60026
- Active, not recruiting
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, United States, 60030
- Active, not recruiting
- Northwestern Medicine Grayslake Outpatient Center
-
Hazel Crest, Illinois, United States, 60429
- Recruiting
- Advocate South Suburban Hospital
-
Contact:
- Site Public Contact
- Phone Number: 708-799-9995
-
Principal Investigator:
- Rebecca E. McFall
-
Highland Park, Illinois, United States, 60035
- Recruiting
- NorthShore University HealthSystem-Highland Park Hospital
-
Contact:
- Site Public Contact
- Phone Number: 847-570-2109
-
Principal Investigator:
- Robert M. Eisner
-
Lake Forest, Illinois, United States, 60045
- Active, not recruiting
- Northwestern Medicine Lake Forest Hospital
-
Libertyville, Illinois, United States, 60048
- Recruiting
- AMG Libertyville - Oncology
-
Contact:
- Site Public Contact
- Phone Number: 630-929-6129
- Email: advocateresearch@advocatehealth.com
-
Principal Investigator:
- Rebecca E. McFall
-
Libertyville, Illinois, United States, 60048
- Recruiting
- Condell Memorial Hospital
-
Contact:
- Site Public Contact
- Phone Number: 630-929-6129
- Email: advocateresearch@advocatehealth.com
-
Principal Investigator:
- Rebecca E. McFall
-
Mattoon, Illinois, United States, 61938
- Recruiting
- Carle Physician Group-Mattoon/Charleston
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Priyank P. Patel
-
Maywood, Illinois, United States, 60153
- Recruiting
- Loyola University Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 708-226-4357
-
Principal Investigator:
- Eugene Suh
-
Naperville, Illinois, United States, 60540
- Recruiting
- Edward Hospital/Cancer Center
-
Principal Investigator:
- Joseph Heng
-
Contact:
- Site Public Contact
- Phone Number: 630-646-6075
-
O'Fallon, Illinois, United States, 62269
- Recruiting
- HSHS Saint Elizabeth's Hospital
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 217-876-4762
- Email: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, United States, 60453-2699
- Recruiting
- Advocate Christ Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 800-323-8622
-
Principal Investigator:
- Rebecca E. McFall
-
Oak Lawn, Illinois, United States, 60453
- Recruiting
- Advocate Children's Hospital-Oak Lawn
-
Contact:
- Site Public Contact
- Phone Number: 847-723-7570
-
Principal Investigator:
- Rebecca E. McFall
-
Orland Park, Illinois, United States, 60462
- Recruiting
- Northwestern Medicine Orland Park
-
Principal Investigator:
- Jane N. Winter
-
Contact:
- Site Public Contact
- Email: nctnprogram_rhlccc@northwestern.edu
-
Park Ridge, Illinois, United States, 60068
- Recruiting
- Advocate Lutheran General Hospital
-
Contact:
- Site Public Contact
- Phone Number: 847-384-3621
-
Principal Investigator:
- Rebecca E. McFall
-
Park Ridge, Illinois, United States, 60068
- Recruiting
- Advocate Children's Hospital-Park Ridge
-
Contact:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Principal Investigator:
- Rebecca E. McFall
-
Peoria, Illinois, United States, 61637
- Recruiting
- OSF Children's Hospital of Illinois
-
Principal Investigator:
- Prerna Kumar
-
Contact:
- Site Public Contact
- Phone Number: 309-624-4945
- Email: ChildrensHospitalofIllinois@osfhealthcare.org
-
Plainfield, Illinois, United States, 60585
- Recruiting
- Edward Hospital/Cancer Center?Plainfield
-
Principal Investigator:
- Joseph Heng
-
Contact:
- Site Public Contact
- Phone Number: 630-646-6075
- Email: Cancerresearch@edward.org
-
Rockford, Illinois, United States, 61114
- Recruiting
- UW Health Carbone Cancer Center Rockford
-
Contact:
- Site Public Contact
- Phone Number: 779-696-9378
- Email: lkline@uwhealth.org
-
Principal Investigator:
- Fahrettin Covut
-
Shiloh, Illinois, United States, 62269
- Recruiting
- Memorial Hospital East
-
Contact:
- Site Public Contact
- Phone Number: 314-747-9912
- Email: dschwab@wustl.edu
-
Principal Investigator:
- Nancy L. Bartlett
-
Springfield, Illinois, United States, 62702
- Recruiting
- Southern Illinois University School of Medicine
-
Contact:
- Site Public Contact
- Phone Number: 217-545-7929
-
Principal Investigator:
- Gregory P. Brandt
-
Urbana, Illinois, United States, 61801
- Recruiting
- Carle Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-446-5532
- Email: Research@carle.com
-
Principal Investigator:
- Priyank P. Patel
-
Warrenville, Illinois, United States, 60555
- Recruiting
- Northwestern Medicine Cancer Center Warrenville
-
Principal Investigator:
- Jane N. Winter
-
Contact:
- Site Public Contact
- Phone Number: 630-352-5360
- Email: Donald.Smith3@nm.org
-
Yorkville, Illinois, United States, 60560
- Recruiting
- Rush-Copley Healthcare Center
-
Contact:
- Site Public Contact
- Phone Number: 630-978-6212
- Email: Cancer.Research@rushcopley.com
-
Principal Investigator:
- Priyank P. Patel
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Riley Hospital for Children
-
Contact:
- Site Public Contact
- Phone Number: 800-248-1199
-
Principal Investigator:
- Jennifer A. Belsky
-
Indianapolis, Indiana, United States, 46260
- Recruiting
- Ascension Saint Vincent Indianapolis Hospital
-
Contact:
- Site Public Contact
- Phone Number: 317-338-2194
- Email: research@stvincent.org
-
Principal Investigator:
- Bassem I. Razzouk
-
-
Iowa
-
Ankeny, Iowa, United States, 50023
- Recruiting
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Principal Investigator:
- Seema Harichand-Herdt
-
Carroll, Iowa, United States, 51401
- Recruiting
- Saint Anthony Regional Hospital
-
Contact:
- Site Public Contact
- Phone Number: 515-689-7658
- Email: sbenson@iora.org
-
Principal Investigator:
- Seema Harichand-Herdt
-
Clive, Iowa, United States, 50325
- Recruiting
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Principal Investigator:
- Seema Harichand-Herdt
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Blank Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 515-241-8912
- Email: samantha.mallory@unitypoint.org
-
Principal Investigator:
- Samantha L. Mallory
-
Des Moines, Iowa, United States, 50309
- Recruiting
- Iowa Methodist Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 515-241-6727
-
Principal Investigator:
- Seema Harichand-Herdt
-
Des Moines, Iowa, United States, 50309
- Recruiting
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Principal Investigator:
- Seema Harichand-Herdt
-
Des Moines, Iowa, United States, 50314
- Recruiting
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Principal Investigator:
- Seema Harichand-Herdt
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa/Holden Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-237-1225
-
Principal Investigator:
- Andrew P. Groves
-
Waukee, Iowa, United States, 50263
- Recruiting
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contact:
- Site Public Contact
- Phone Number: 515-241-3305
-
Principal Investigator:
- Seema Harichand-Herdt
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Recruiting
- Wesley Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 316-962-7802
- Email: WesleyResearch@wesleymc.com
-
Principal Investigator:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Recruiting
- University of Kentucky/Markey Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 859-257-3379
-
Principal Investigator:
- James T. Badgett
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 502-629-5500
- Email: CancerResource@nortonhealthcare.org
-
Principal Investigator:
- Michael J. Ferguson
-
Louisville, Kentucky, United States, 40245
- Recruiting
- UofL Health Medical Center Northeast
-
Contact:
- Site Public Contact
- Phone Number: 502-852-2755
- Email: ctoinfo@louisville.edu
-
Principal Investigator:
- Hassaan Yasin
-
Louisville, Kentucky, United States, 40202
- Suspended
- The James Graham Brown Cancer Center at University of Louisville
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70118
- Recruiting
- Children's Hospital New Orleans
-
Principal Investigator:
- Maria C. Velez-Yanguas
-
Contact:
- Site Public Contact
- Phone Number: 504-894-5377
-
New Orleans, Louisiana, United States, 70121
- Recruiting
- Ochsner Medical Center Jefferson
-
Contact:
- Site Public Contact
- Phone Number: 504-842-8084
- Email: Elisemarie.curry@ochsner.org
-
Principal Investigator:
- Craig Lotterman
-
-
Maine
-
Bangor, Maine, United States, 04401
- Recruiting
- Eastern Maine Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 207-973-4274
-
Principal Investigator:
- Daniel L. Callaway
-
Bath, Maine, United States, 04530
- Recruiting
- MaineHealth Coastal Cancer Treatment Center
-
Contact:
- Site Public Contact
- Phone Number: 888-823-5923
- Email: ctsucontact@westat.com
-
Principal Investigator:
- Nadav L. Kastle
-
Portland, Maine, United States, 04102
- Recruiting
- MaineHealth Maine Medical Center - Portland
-
Principal Investigator:
- Nadav L. Kastle
-
Contact:
- Site Public Contact
- Phone Number: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
Sanford, Maine, United States, 04073
- Recruiting
- MaineHealth Cancer Care Center of York County
-
Contact:
- Site Public Contact
- Phone Number: 207-459-1600
-
Principal Investigator:
- Nadav L. Kastle
-
Scarborough, Maine, United States, 04074
- Recruiting
- Maine Children's Cancer Program
-
Principal Investigator:
- Nadav L. Kastle
-
Contact:
- Site Public Contact
- Phone Number: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
Scarborough, Maine, United States, 04074
- Recruiting
- MaineHealth Maine Medical Center- Scarborough
-
Principal Investigator:
- Nadav L. Kastle
-
Contact:
- Site Public Contact
- Phone Number: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
South Portland, Maine, United States, 04106
- Recruiting
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Principal Investigator:
- Nadav L. Kastle
-
Contact:
- Site Public Contact
- Phone Number: 207-396-8670
- Email: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Principal Investigator:
- Stacy L. Cooper
-
Contact:
- Site Public Contact
- Phone Number: 410-955-8804
- Email: jhcccro@jhmi.edu
-
Baltimore, Maryland, United States, 21215
- Recruiting
- Sinai Hospital of Baltimore
-
Principal Investigator:
- Jason M. Fixler
-
Contact:
- Site Public Contact
- Phone Number: 410-601-9083
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland/Greenebaum Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-888-8823
-
Principal Investigator:
- Teresa A. York
-
Bethesda, Maryland, United States, 20889-5600
- Recruiting
- Walter Reed National Military Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 301-319-2100
-
Principal Investigator:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute
-
Principal Investigator:
- Ann S. LaCasce
-
Contact:
- Site Public Contact
- Phone Number: 877-442-3324
-
Worcester, Massachusetts, United States, 01655
- Recruiting
- UMass Memorial Medical Center - University Campus
-
Contact:
- Site Public Contact
- Phone Number: 508-856-3216
- Email: cancer.research@umassmed.edu
-
Principal Investigator:
- Stefanie R. Lowas
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- C S Mott Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 800-865-1125
-
Principal Investigator:
- Emily B. Walling
-
Ann Arbor, Michigan, United States, 48106
- Recruiting
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Battle Creek, Michigan, United States, 49017
- Recruiting
- Bronson Battle Creek
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Brighton, Michigan, United States, 48114
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Brownstown, Michigan, United States, 48183
- Recruiting
- Henry Ford Cancer Institute-Downriver
-
Contact:
- Site Public Contact
- Phone Number: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Canton, Michigan, United States, 48188
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Chelsea, Michigan, United States, 48118
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Clinton Township, Michigan, United States, 48038
- Recruiting
- Henry Ford Macomb Hospital-Clinton Township
-
Contact:
- Site Public Contact
- Phone Number: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Dearborn, Michigan, United States, 48126
- Recruiting
- Henry Ford Medical Center-Fairlane
-
Contact:
- Site Public Contact
- Phone Number: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Dearborn, Michigan, United States, 48124
- Recruiting
- Corewell Health Dearborn Hospital
-
Contact:
- Site Public Contact
- Phone Number: 248-551-7695
-
Principal Investigator:
- Marie V. Nelson
-
Detroit, Michigan, United States, 48201
- Recruiting
- Wayne State University/Karmanos Cancer Institute
-
Principal Investigator:
- Dipenkumar Modi
-
Contact:
- Site Public Contact
- Phone Number: 800-527-6266
- Email: ctoadmin@karmanos.org
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Hospital
-
Contact:
- Site Public Contact
- Phone Number: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Detroit, Michigan, United States, 48201
- Recruiting
- Children's Hospital of Michigan
-
Contact:
- Site Public Contact
- Email: helpdesk@childrensoncologygroup.org
-
Principal Investigator:
- Meret Henry
-
East Lansing, Michigan, United States, 48823
- Active, not recruiting
- Michigan State University
-
Farmington Hills, Michigan, United States, 48334
- Recruiting
- Weisberg Cancer Treatment Center
-
Principal Investigator:
- Dipenkumar Modi
-
Contact:
- Site Public Contact
- Phone Number: 313-576-9790
- Email: ctoadmin@karmanos.org
-
Farmington Hills, Michigan, United States, 48336
- Recruiting
- Corewell Health Farmington Hills Hospital
-
Contact:
- Site Public Contact
- Phone Number: 248-551-7695
-
Principal Investigator:
- Marie V. Nelson
-
Grand Rapids, Michigan, United States, 49503
- Suspended
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Grand Rapids, Michigan, United States, 49503
- Recruiting
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Jackson, Michigan, United States, 49201
- Recruiting
- Allegiance Health
-
Contact:
- Site Public Contact
- Phone Number: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Kalamazoo, Michigan, United States, 49007
- Recruiting
- Bronson Methodist Hospital
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, United States, 49007
- Recruiting
- West Michigan Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, United States, 49009
- Suspended
- Beacon Kalamazoo Cancer Center
-
Livonia, Michigan, United States, 48154
- Recruiting
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Muskegon, Michigan, United States, 49444
- Suspended
- Trinity Health Muskegon Hospital
-
Norton Shores, Michigan, United States, 49444
- Suspended
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi, Michigan, United States, 48377
- Recruiting
- Henry Ford Medical Center-Columbus
-
Contact:
- Site Public Contact
- Phone Number: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Novi, Michigan, United States, 48374
- Suspended
- Henry Ford Health Providence Novi Hospital
-
Pontiac, Michigan, United States, 48341
- Recruiting
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Reed City, Michigan, United States, 49677
- Recruiting
- Corewell Health Reed City Hospital
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Royal Oak, Michigan, United States, 48073
- Recruiting
- Corewell Health William Beaumont University Hospital
-
Contact:
- Site Public Contact
- Phone Number: 248-551-7695
-
Principal Investigator:
- Marie V. Nelson
-
Royal Oak, Michigan, United States, 48073
- Recruiting
- Corewell Health Children's
-
Contact:
- Site Public Contact
- Phone Number: 248-551-7695
-
Principal Investigator:
- Marie V. Nelson
-
Saint Joseph, Michigan, United States, 49085
- Recruiting
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Southfield, Michigan, United States, 48075
- Recruiting
- Henry Ford Health Providence Southfield Hospital
-
Principal Investigator:
- Philip Kuriakose
-
Contact:
- Site Public Contact
- Phone Number: 248-849-5332
- Email: kfife3@hfhs.org
-
Traverse City, Michigan, United States, 49684
- Recruiting
- Munson Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Troy, Michigan, United States, 48085
- Recruiting
- Corewell Health Beaumont Troy Hospital
-
Contact:
- Site Public Contact
- Phone Number: 248-551-7695
-
Principal Investigator:
- Marie V. Nelson
-
West Bloomfield, Michigan, United States, 48322
- Recruiting
- Henry Ford West Bloomfield Hospital
-
Contact:
- Site Public Contact
- Phone Number: 313-916-3721
- Email: CTOResearch@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Wyandotte, Michigan, United States, 48192
- Recruiting
- Henry Ford Wyandotte Hospital
-
Contact:
- Site Public Contact
- Email: nhay@hfhs.org
-
Principal Investigator:
- Philip Kuriakose
-
Wyoming, Michigan, United States, 49519
- Recruiting
- University of Michigan Health - West
-
Contact:
- Site Public Contact
- Phone Number: 616-391-1230
- Email: crcwm-regulatory@crcwm.org
-
Principal Investigator:
- Kathleen Y. Butler
-
Ypsilanti, Michigan, United States, 48197
- Recruiting
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contact:
- Site Public Contact
- Phone Number: 734-712-7251
- Email: MCRCwebsitecontactform@stjoeshealth.org
-
Principal Investigator:
- Christopher M. Reynolds
-
-
Minnesota
-
Coon Rapids, Minnesota, United States, 55433
- Recruiting
- Mercy Hospital
-
Contact:
- Site Public Contact
- Phone Number: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Principal Investigator:
- David M. King
-
Edina, Minnesota, United States, 55435
- Recruiting
- Fairview Southdale Hospital
-
Contact:
- Site Public Contact
- Phone Number: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Principal Investigator:
- David M. King
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Principal Investigator:
- Michael K. Richards
-
Contact:
- Site Public Contact
- Phone Number: 612-813-5913
- Email: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, United States, 55407
- Recruiting
- Abbott-Northwestern Hospital
-
Contact:
- Site Public Contact
- Phone Number: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Principal Investigator:
- David M. King
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota/Masonic Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 612-624-2620
-
Principal Investigator:
- Peter M. Gordon
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Principal Investigator:
- Mira Kohorst
-
Contact:
- Site Public Contact
- Phone Number: 855-776-0015
-
Saint Louis Park, Minnesota, United States, 55416
- Recruiting
- Park Nicollet Clinic - Saint Louis Park
-
Contact:
- Site Public Contact
- Phone Number: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Principal Investigator:
- David M. King
-
Saint Paul, Minnesota, United States, 55101
- Recruiting
- Regions Hospital
-
Contact:
- Site Public Contact
- Phone Number: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Principal Investigator:
- David M. King
-
Saint Paul, Minnesota, United States, 55102
- Recruiting
- United Hospital
-
Contact:
- Site Public Contact
- Phone Number: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Principal Investigator:
- David M. King
-
Woodbury, Minnesota, United States, 55125
- Recruiting
- Minnesota Oncology Hematology PA-Woodbury
-
Contact:
- Site Public Contact
- Phone Number: 952-993-1517
- Email: mmcorc@healthpartners.com
-
Principal Investigator:
- David M. King
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- Recruiting
- University of Mississippi Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 601-815-6700
-
Principal Investigator:
- Amanda Strobel
-
-
Missouri
-
Cape Girardeau, Missouri, United States, 63703
- Recruiting
- Saint Francis Medical Center
-
Principal Investigator:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Phone Number: 573-334-2230
- Email: sfmc@sfmc.net
-
Chesterfield, Missouri, United States, 63017
- Recruiting
- Saint Luke's Hospital
-
Principal Investigator:
- Mark J. Fesler
-
Contact:
- Site Public Contact
- Phone Number: 314-205-6936
-
City of Saint Peters, Missouri, United States, 63376
- Recruiting
- Siteman Cancer Center at Saint Peters Hospital
-
Principal Investigator:
- Nancy L. Bartlett
-
Contact:
- Site Public Contact
- Phone Number: 800-600-3606
- Email: info@siteman.wustl.edu
-
Columbia, Missouri, United States, 65212
- Recruiting
- University of Missouri Children's Hospital
-
Principal Investigator:
- Barbara A. Gruner
-
Contact:
- Site Public Contact
- Phone Number: 573-882-1960
- Email: snwq62@health.missouri.edu
-
Creve Coeur, Missouri, United States, 63141
- Recruiting
- Siteman Cancer Center at West County Hospital
-
Principal Investigator:
- Nancy L. Bartlett
-
Contact:
- Site Public Contact
- Phone Number: 800-600-3606
- Email: info@siteman.wustl.edu
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Hospitals and Clinics
-
Principal Investigator:
- Keith J. August
-
Contact:
- Site Public Contact
- Phone Number: 816-302-6808
- Email: COGResearchGroup@cmh.edu
-
St Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Principal Investigator:
- Nancy L. Bartlett
-
Contact:
- Site Public Contact
- Phone Number: 800-600-3606
- Email: info@siteman.wustl.edu
-
St Louis, Missouri, United States, 63141
- Recruiting
- Mercy Hospital Saint Louis
-
Contact:
- Site Public Contact
- Phone Number: 314-251-7066
-
Principal Investigator:
- Robin D. Hanson
-
St Louis, Missouri, United States, 63104
- Recruiting
- Cardinal Glennon Children's Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 314-268-4000
-
Principal Investigator:
- William S. Ferguson
-
St Louis, Missouri, United States, 63129
- Recruiting
- Siteman Cancer Center-South County
-
Principal Investigator:
- Nancy L. Bartlett
-
Contact:
- Site Public Contact
- Phone Number: 800-600-3606
- Email: info@siteman.wustl.edu
-
St Louis, Missouri, United States, 63136
- Recruiting
- Siteman Cancer Center at Christian Hospital
-
Principal Investigator:
- Nancy L. Bartlett
-
Contact:
- Site Public Contact
- Phone Number: 800-600-3606
- Email: info@siteman.wustl.edu
-
-
Nebraska
-
Bellevue, Nebraska, United States, 68123
- Recruiting
- Nebraska Medicine-Bellevue
-
Contact:
- Site Public Contact
- Phone Number: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Principal Investigator:
- Jill C. Beck
-
Omaha, Nebraska, United States, 68114
- Recruiting
- Children's Hospital and Medical Center of Omaha
-
Contact:
- Site Public Contact
- Phone Number: 402-955-3949
-
Principal Investigator:
- Jill C. Beck
-
Omaha, Nebraska, United States, 68198
- Recruiting
- University of Nebraska Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 402-559-6941
- Email: unmcrsa@unmc.edu
-
Principal Investigator:
- Jill C. Beck
-
Omaha, Nebraska, United States, 68118
- Recruiting
- Nebraska Medicine-Village Pointe
-
Contact:
- Site Public Contact
- Phone Number: 402-559-5600
-
Principal Investigator:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, United States, 89135
- Recruiting
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Contact:
- Site Public Contact
- Phone Number: 702-384-0013
- Email: research@sncrf.org
-
Principal Investigator:
- Alan K. Ikeda
-
Reno, Nevada, United States, 89502
- Recruiting
- Renown Regional Medical Center
-
Principal Investigator:
- Seema L. Rao
-
Contact:
- Site Public Contact
- Phone Number: 775-982-5050
- Email: Renown-CRD@renown.org
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Recruiting
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Principal Investigator:
- Angela Ricci
-
Contact:
- Site Public Contact
- Phone Number: 800-639-6918
- Email: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Recruiting
- Cooper Hospital University Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 856-325-6757
-
Principal Investigator:
- Sushil Ghimire
-
Elizabeth, New Jersey, United States, 07207
- Recruiting
- Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
-
Contact:
- Site Public Contact
- Phone Number: 908-994-8000
-
Principal Investigator:
- Richard A. Drachtman
-
Flemington, New Jersey, United States, 08822
- Recruiting
- Hunterdon Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 908-237-2330
-
Principal Investigator:
- Myron E. Bednar
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack University Medical Center
-
Principal Investigator:
- Burton E. Appel
-
Contact:
- Site Public Contact
- Phone Number: 551-996-2897
-
Jersey City, New Jersey, United States, 07302
- Recruiting
- Jersey City Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 888-823-5923
- Email: ctsucontact@westat.com
-
Principal Investigator:
- Richard A. Drachtman
-
Livingston, New Jersey, United States, 07039
- Recruiting
- Cooperman Barnabas Medical Center
-
Principal Investigator:
- Richard A. Drachtman
-
Contact:
- Site Public Contact
- Phone Number: 973-322-5200
-
Long Branch, New Jersey, United States, 07740
- Recruiting
- Monmouth Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 732-923-6564
- Email: mary.danish@rwjbh.org
-
Principal Investigator:
- Richard A. Drachtman
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Morristown Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 973-971-5900
-
Principal Investigator:
- Kathryn L. Laurie
-
Neptune City, New Jersey, United States, 07753
- Recruiting
- Jersey Shore Medical Center
-
Principal Investigator:
- Burton E. Appel
-
Contact:
- Site Public Contact
- Phone Number: 732-776-4240
-
New Brunswick, New Jersey, United States, 08903
- Recruiting
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Site Public Contact
- Phone Number: 732-235-7356
-
Principal Investigator:
- Richard A. Drachtman
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Saint Peter's University Hospital
-
Contact:
- Site Public Contact
- Phone Number: 6163 732-745-8600
- Email: kcovert@saintpetersuh.com
-
Principal Investigator:
- Nibal A. Zaghloul
-
New Brunswick, New Jersey, United States, 08903
- Recruiting
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Contact:
- Site Public Contact
- Phone Number: 732-235-8675
-
Principal Investigator:
- Richard A. Drachtman
-
Newark, New Jersey, United States, 07112
- Recruiting
- Newark Beth Israel Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 973-926-7230
- Email: Christine.Kosmides@rwjbh.org
-
Principal Investigator:
- Teena Bhatla
-
Paterson, New Jersey, United States, 07503
- Recruiting
- Saint Joseph's Regional Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 973-754-2207
- Email: HallL@sjhmc.org
-
Principal Investigator:
- Alissa Kahn
-
Toms River, New Jersey, United States, 08755
- Recruiting
- Community Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 732-557-8294
- Email: Lennette.Gonzales@rwjbh.org
-
Principal Investigator:
- Richard A. Drachtman
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Recruiting
- Presbyterian Hospital
-
Contact:
- Site Public Contact
- Phone Number: 505-559-6113
- Email: WBurman@phs.org
-
Principal Investigator:
- Beeling Armijo
-
Albuquerque, New Mexico, United States, 87106
- Suspended
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, United States, 12208
- Recruiting
- Albany Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 518-262-5513
-
Principal Investigator:
- Lauren R. Weintraub
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
Contact:
- Site Public Contact
- Phone Number: 800-767-9355
- Email: askroswell@roswellpark.org
-
Principal Investigator:
- Kara M. Kelly
-
Camillus, New York, United States, 13031
- Recruiting
- Hematology Oncology Associates of CNY at Camillus
-
Contact:
- Site Public Contact
- Phone Number: 315-472-7504
-
Principal Investigator:
- Steven M. Duffy
-
East Syracuse, New York, United States, 13057
- Recruiting
- Hematology Oncology Associates of Central New York-East Syracuse
-
Contact:
- Site Public Contact
- Phone Number: 315-472-7504
-
Principal Investigator:
- Steven M. Duffy
-
Glens Falls, New York, United States, 12801
- Active, not recruiting
- Glens Falls Hospital
-
Mineola, New York, United States, 11501
- Recruiting
- NYU Langone Hospital - Long Island
-
Contact:
- Site Public Contact
- Phone Number: 212-263-4432
- Email: cancertrials@nyulangone.org
-
Principal Investigator:
- Chana L. Glasser
-
New Hyde Park, New York, United States, 11040
- Recruiting
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Contact:
- Site Public Contact
- Phone Number: 718-470-3460
-
Principal Investigator:
- Arlene S. Redner
-
New York, New York, United States, 10032
- Recruiting
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Principal Investigator:
- Nobuko Hijiya
-
Contact:
- Site Public Contact
- Phone Number: 212-342-5162
- Email: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 212-639-7592
-
Principal Investigator:
- Christopher J. Forlenza
-
New York, New York, United States, 10016
- Recruiting
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Principal Investigator:
- Elizabeth A. Raetz
-
Contact:
- Site Public Contact
- Email: CancerTrials@nyulangone.org
-
New York, New York, United States, 10029
- Recruiting
- Mount Sinai Hospital
-
Contact:
- Site Public Contact
- Phone Number: 212-824-7309
- Email: CCTO@mssm.edu
-
Principal Investigator:
- Pamela R. Merola
-
New York, New York, United States, 10065
- Recruiting
- NYP/Weill Cornell Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 212-746-1848
-
Principal Investigator:
- Nitya Gulati
-
Rochester, New York, United States, 14642
- Recruiting
- University of Rochester
-
Contact:
- Site Public Contact
- Phone Number: 585-275-5830
-
Principal Investigator:
- Carla Casulo
-
Stony Brook, New York, United States, 11794
- Recruiting
- Stony Brook University Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 800-862-2215
-
Principal Investigator:
- Laura E. Hogan
-
Syracuse, New York, United States, 13210
- Recruiting
- State University of New York Upstate Medical University
-
Contact:
- Site Public Contact
- Phone Number: 315-464-5476
-
Principal Investigator:
- Melanie A. Comito
-
The Bronx, New York, United States, 10467
- Recruiting
- Montefiore Medical Center - Moses Campus
-
Contact:
- Site Public Contact
- Phone Number: 718-379-6866
- Email: eskwak@montefiore.org
-
Principal Investigator:
- Alice Lee
-
Webster, New York, United States, 14580
- Recruiting
- Wilmot Cancer Institute at Webster
-
Contact:
- Site Public Contact
- Email: WCICTOresearch@urmc.rochester.edu
-
Principal Investigator:
- Carla Casulo
-
Williamsville, New York, United States, 14221
- Recruiting
- Roswell Park Amherst Center
-
Contact:
- Site Public Contact
- Phone Number: 800-767-9355
- Email: askroswell@roswellpark.org
-
Principal Investigator:
- Kara M. Kelly
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Recruiting
- Mission Hospital
-
Contact:
- Site Public Contact
- Phone Number: 828-213-7055
- Email: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Principal Investigator:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- UNC Lineberger Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 877-668-0683
- Email: cancerclinicaltrials@med.unc.edu
-
Principal Investigator:
- Natalie S. Grover
-
Charlotte, North Carolina, United States, 28203
- Recruiting
- Carolinas Medical Center/Levine Cancer Institute
-
Contact:
- Site Public Contact
- Phone Number: 800-804-9376
-
Principal Investigator:
- Joel A. Kaplan
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Novant Health Presbyterian Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 980-201-6360
- Email: kashah@novanthealth.org
-
Principal Investigator:
- Holly Edington
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center
-
Principal Investigator:
- Jessica M. Sun
-
Contact:
- Site Public Contact
- Phone Number: 888-275-3853
-
Greenville, North Carolina, United States, 27834
- Recruiting
- East Carolina University
-
Contact:
- Site Public Contact
- Phone Number: 252-744-1015
- Email: eubankss@ecu.edu
-
Principal Investigator:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest University Health Sciences
-
Contact:
- Site Public Contact
- Phone Number: 336-713-6771
-
Principal Investigator:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- Recruiting
- Sanford Broadway Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 701-323-5760
- Email: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Principal Investigator:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Recruiting
- Children's Hospital Medical Center of Akron
-
Contact:
- Site Public Contact
- Phone Number: 330-543-3193
-
Principal Investigator:
- Erin Wright
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 513-636-2799
- Email: cancer@cchmc.org
-
Principal Investigator:
- Robin E. Norris
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic Foundation
-
Contact:
- Site Public Contact
- Phone Number: 866-223-8100
- Email: TaussigResearch@ccf.org
-
Principal Investigator:
- Matteo M. Trucco
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Rainbow Babies and Childrens Hospital
-
Contact:
- Site Public Contact
- Phone Number: 216-844-5437
-
Principal Investigator:
- Duncan S. Stearns
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 614-722-6039
- Email: Melinda.Triplet@nationwidechildrens.org
-
Principal Investigator:
- Mark A. Ranalli
-
Dayton, Ohio, United States, 45404
- Recruiting
- Dayton Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 800-228-4055
-
Principal Investigator:
- Jordan M. Wright
-
Toledo, Ohio, United States, 43606
- Recruiting
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 419-824-1842
- Email: PCIOncResearch@promedica.org
-
Principal Investigator:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Phone Number: 405-271-8777
- Email: ou-clinical-trials@ouhsc.edu
-
Principal Investigator:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, United States, 74136
- Recruiting
- Saint Francis Children's Hospital
-
Principal Investigator:
- Jill A. Salo
-
Contact:
- Site Public Contact
- Phone Number: 918-502-6720
-
-
Oregon
-
Baker City, Oregon, United States, 97814
- Recruiting
- Saint Alphonsus Cancer Care Center-Baker City
-
Contact:
- Site Public Contact
- Phone Number: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Newberg, Oregon, United States, 97132
- Suspended
- Providence Newberg Medical Center
-
Ontario, Oregon, United States, 97914
- Recruiting
- Saint Alphonsus Cancer Care Center-Ontario
-
Contact:
- Site Public Contact
- Phone Number: 406-969-6060
- Email: mccinfo@mtcancer.org
-
Principal Investigator:
- Christopher M. Reynolds
-
Oregon City, Oregon, United States, 97045
- Suspended
- Providence Willamette Falls Medical Center
-
Portland, Oregon, United States, 97227
- Recruiting
- Legacy Emanuel Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 503-413-2560
-
Principal Investigator:
- Jason M. Glover
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health and Science University
-
Contact:
- Site Public Contact
- Phone Number: 503-494-1080
- Email: trials@ohsu.edu
-
Principal Investigator:
- Bill H. Chang
-
Portland, Oregon, United States, 97213
- Recruiting
- Providence Portland Medical Center
-
Principal Investigator:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Phone Number: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
Portland, Oregon, United States, 97225
- Recruiting
- Providence Saint Vincent Medical Center
-
Principal Investigator:
- Dan S. Zuckerman
-
Contact:
- Site Public Contact
- Phone Number: 503-215-2614
- Email: CanRsrchStudies@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Recruiting
- Lehigh Valley Hospital-Cedar Crest
-
Principal Investigator:
- Christopher M. Reynolds
-
Contact:
- Site Public Contact
- Phone Number: 610-402-9543
- Email: Morgan_M.Horton@lvhn.org
-
Danville, Pennsylvania, United States, 17822
- Recruiting
- Geisinger Medical Center
-
Principal Investigator:
- Jagadeesh Ramdas
-
Contact:
- Site Public Contact
- Phone Number: 570-271-5251
- Email: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 717-531-6012
-
Principal Investigator:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Site Public Contact
- Phone Number: 267-425-5544
- Email: CancerTrials@email.chop.edu
-
Principal Investigator:
- Leslie S. Kersun
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University Hospital
-
Contact:
- Site Public Contact
- Phone Number: 215-600-9151
- Email: ONCTrialNow@jefferson.edu
-
Principal Investigator:
- Seyfettin O. Alpdogan
-
Philadelphia, Pennsylvania, United States, 19134
- Recruiting
- Saint Christopher's Hospital for Children
-
Contact:
- Site Public Contact
- Phone Number: 215-427-8991
-
Principal Investigator:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- Children's Hospital of Pittsburgh of UPMC
-
Contact:
- Site Public Contact
- Phone Number: 412-692-8570
- Email: jean.tersak@chp.edu
-
Principal Investigator:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Recruiting
- Rhode Island Hospital
-
Principal Investigator:
- Bradley DeNardo
-
Contact:
- Site Public Contact
- Phone Number: 401-444-1488
-
Westerly, Rhode Island, United States, 02891
- Recruiting
- Smilow Cancer Hospital Care Center - Westerly
-
Contact:
- Site Public Contact
- Phone Number: 203-785-5702
- Email: canceranswers@yale.edu
-
Principal Investigator:
- Farzana Pashankar
-
-
South Carolina
-
Boiling Springs, South Carolina, United States, 29316
- Recruiting
- Prisma Health Cancer Institute - Spartanburg
-
Principal Investigator:
- Aniket Saha
-
Contact:
- Site Public Contact
- Phone Number: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- Site Public Contact
- Phone Number: 843-792-9321
- Email: hcc-clinical-trials@musc.edu
-
Principal Investigator:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, United States, 29203
- Recruiting
- Prisma Health Richland Hospital
-
Principal Investigator:
- Stuart L. Cramer
-
Contact:
- Site Public Contact
- Phone Number: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, United States, 29605
- Recruiting
- BI-LO Charities Children's Cancer Center
-
Principal Investigator:
- Aniket Saha
-
Contact:
- Site Public Contact
- Phone Number: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, United States, 29601
- Recruiting
- Saint Francis Hospital
-
Principal Investigator:
- Stephen H. Dyar
-
Contact:
- Site Public Contact
- Phone Number: 864-603-6234
- Email: Heather_Rich@bshsi.org
-
Greenville, South Carolina, United States, 29607
- Recruiting
- Saint Francis Cancer Center
-
Principal Investigator:
- Stephen H. Dyar
-
Contact:
- Site Public Contact
- Phone Number: 864-603-6234
- Email: Heather_Rich@bshsi.org
-
Greenville, South Carolina, United States, 29615
- Recruiting
- Prisma Health Cancer Institute - Eastside
-
Principal Investigator:
- Aniket Saha
-
Contact:
- Site Public Contact
- Phone Number: 864-522-4317
- Email: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57117-5134
- Recruiting
- Sanford USD Medical Center - Sioux Falls
-
Contact:
- Site Public Contact
- Phone Number: 605-312-3320
- Email: OncologyClinicalTrialsSF@SanfordHealth.org
-
Principal Investigator:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
- Recruiting
- T C Thompson Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 423-778-7289
-
Principal Investigator:
- Benjamin A. Mixon
-
Knoxville, Tennessee, United States, 37916
- Recruiting
- East Tennessee Childrens Hospital
-
Contact:
- Site Public Contact
- Phone Number: 865-541-8266
-
Principal Investigator:
- Susan E. Spiller
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt University/Ingram Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 800-811-8480
-
Principal Investigator:
- Christine M. Smith
-
Nashville, Tennessee, United States, 37203
- Recruiting
- The Children's Hospital at TriStar Centennial
-
Contact:
- Site Public Contact
- Phone Number: 615-342-1919
-
Principal Investigator:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, United States, 78723
- Recruiting
- Dell Children's Medical Center of Central Texas
-
Contact:
- Site Public Contact
- Phone Number: 512-628-1902
- Email: TXAUS-DL-SFCHemonc.research@ascension.org
-
Principal Investigator:
- Shannon M. Cohn
-
Corpus Christi, Texas, United States, 78411
- Recruiting
- Driscoll Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 361-694-5311
- Email: Crystal.DeLosSantos@dchstx.org
-
Principal Investigator:
- Nkechi I. Mba
-
Dallas, Texas, United States, 75390
- Recruiting
- UT Southwestern/Simmons Cancer Center-Dallas
-
Principal Investigator:
- Ksenya Shliakhtsitsava
-
Contact:
- Site Public Contact
- Phone Number: 214-648-7097
- Email: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, United States, 75230
- Recruiting
- Medical City Dallas Hospital
-
Contact:
- Site Public Contact
- Phone Number: 972-566-5588
-
Principal Investigator:
- Maurizio L. Ghisoli
-
El Paso, Texas, United States, 79905
- Recruiting
- El Paso Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 915-298-5444
- Email: ranjan.bista@ttuhsc.edu
-
Principal Investigator:
- Benjamin Carcamo
-
Fort Worth, Texas, United States, 76104
- Recruiting
- Cook Children's Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 682-885-2103
- Email: CookChildrensResearch@cookchildrens.org
-
Principal Investigator:
- Karen H. Albritton
-
Houston, Texas, United States, 77030
- Recruiting
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 713-798-1354
- Email: burton@bcm.edu
-
Principal Investigator:
- Kala Y. Kamdar
-
Houston, Texas, United States, 77030
- Recruiting
- UT MD Anderson Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 866-632-6789
- Email: askmdanderson@mdanderson.org
-
Principal Investigator:
- Najat C. Daw
-
Lubbock, Texas, United States, 79410
- Recruiting
- Covenant Children's Hospital
-
Principal Investigator:
- Kishor M. Bhende
-
Contact:
- Site Public Contact
- Phone Number: 806-725-8657
- Email: mbisbee@providence.org
-
Lubbock, Texas, United States, 79415
- Recruiting
- UMC Cancer Center / UMC Health System
-
Contact:
- Site Public Contact
- Phone Number: 806-775-8590
-
Principal Investigator:
- Erin K. Barr
-
San Antonio, Texas, United States, 78207
- Recruiting
- Children's Hospital of San Antonio
-
Contact:
- Site Public Contact
- Phone Number: 210-704-2894
- Email: bridget.medina@christushealth.org
-
Principal Investigator:
- Julie Voeller
-
San Antonio, Texas, United States, 78229
- Recruiting
- University of Texas Health Science Center at San Antonio
-
Contact:
- Site Public Contact
- Phone Number: 210-450-3800
- Email: phoresearchoffice@uthscsa.edu
-
Principal Investigator:
- Allison C. Grimes
-
San Antonio, Texas, United States, 78229
- Recruiting
- Methodist Children's Hospital of South Texas
-
Contact:
- Site Public Contact
- Phone Number: 210-575-6240
- Email: Vinod.GidvaniDiaz@hcahealthcare.com
-
Principal Investigator:
- Jose M. Esquilin
-
Temple, Texas, United States, 76508
- Recruiting
- Scott and White Memorial Hospital
-
Contact:
- Site Public Contact
- Phone Number: 254-724-5407
-
Principal Investigator:
- Nicholas W. McGregor
-
-
Utah
-
Salt Lake City, Utah, United States, 84113
- Recruiting
- Primary Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 801-585-5270
-
Principal Investigator:
- Mallorie B. Heneghan
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Huntsman Cancer Institute/University of Utah
-
Principal Investigator:
- Boyu Hu
-
Contact:
- Site Public Contact
- Phone Number: 888-424-2100
- Email: cancerinfo@hci.utah.edu
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- Recruiting
- University of Vermont and State Agricultural College
-
Contact:
- Site Public Contact
- Phone Number: 802-656-8990
- Email: rpo@uvm.edu
-
Principal Investigator:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- University of Virginia Cancer Center
-
Contact:
- Site Public Contact
- Phone Number: 434-243-6303
- Email: uvacancertrials@hscmail.mcc.virginia.edu
-
Principal Investigator:
- Brian C. Belyea
-
Falls Church, Virginia, United States, 22042
- Recruiting
- INOVA Fairfax Hospital
-
Contact:
- Site Public Contact
- Phone Number: 703-208-6650
- Email: Stephanie.VanBebber@inova.org
-
Principal Investigator:
- Robin Y. Dulman
-
Norfolk, Virginia, United States, 23507
- Recruiting
- Children's Hospital of The King's Daughters
-
Contact:
- Site Public Contact
- Phone Number: 757-668-7243
- Email: CCBDCresearch@chkd.org
-
Principal Investigator:
- Melissa S. Mark
-
Portsmouth, Virginia, United States, 23708-2197
- Recruiting
- Naval Medical Center - Portsmouth
-
Contact:
- Site Public Contact
- Phone Number: 757-953-5939
-
Principal Investigator:
- Karin Brockman
-
Richmond, Virginia, United States, 23298
- Recruiting
- VCU Massey Comprehensive Cancer Center
-
Principal Investigator:
- Jordyn R. Griffin
-
Contact:
- Site Public Contact
- Phone Number: 804-628-6430
- Email: CTOclinops@vcu.edu
-
Roanoke, Virginia, United States, 24014
- Recruiting
- Carilion Children's
-
Contact:
- Site Public Contact
- Phone Number: 540-266-6238
- Email: wpmccarty@carilionclinic.org
-
Principal Investigator:
- Erwood G. Edwards
-
-
Washington
-
Renton, Washington, United States, 98055
- Recruiting
- Valley Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 425-228-3440
- Email: research@valleymed.org
-
Principal Investigator:
- Alan K. Ikeda
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 866-987-2000
-
Principal Investigator:
- Sarah E. Leary
-
Spokane, Washington, United States, 99204
- Recruiting
- Providence Sacred Heart Medical Center and Children's Hospital
-
Contact:
- Site Public Contact
- Phone Number: 800-228-6618
- Email: HopeBeginsHere@providence.org
-
Principal Investigator:
- Judy L. Felgenhauer
-
Tacoma, Washington, United States, 98405
- Recruiting
- Mary Bridge Children's Hospital and Health Center
-
Contact:
- Site Public Contact
- Phone Number: 253-403-1461
- Email: research@multicare.org
-
Principal Investigator:
- Robert G. Irwin
-
-
West Virginia
-
Charleston, West Virginia, United States, 25304
- Recruiting
- West Virginia University Charleston Division
-
Contact:
- Site Public Contact
- Phone Number: 304-388-9944
-
Principal Investigator:
- Mohamad H. Badawi
-
Huntington, West Virginia, United States, 25701
- Recruiting
- Edwards Comprehensive Cancer Center
-
Principal Investigator:
- Mark A. Ranalli
-
Contact:
- Site Public Contact
- Phone Number: 304-399-6566
- Email: Christina.Cole@chhi.org
-
-
Wisconsin
-
Burlington, Wisconsin, United States, 53105
- Recruiting
- Aurora Cancer Care-Southern Lakes VLCC
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Cudahy, Wisconsin, United States, 53110
- Recruiting
- Aurora Saint Luke's South Shore
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Germantown, Wisconsin, United States, 53022
- Recruiting
- Aurora Health Care Germantown Health Center
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Grafton, Wisconsin, United States, 53024
- Recruiting
- Aurora Cancer Care-Grafton
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Green Bay, Wisconsin, United States, 54311
- Recruiting
- Aurora BayCare Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Green Bay, Wisconsin, United States, 54301
- Recruiting
- Saint Vincent Hospital Cancer Center Green Bay
-
Principal Investigator:
- Catherine A. Long
-
Contact:
- Site Public Contact
- Phone Number: 920-433-8889
- Email: WI_research_admin@hshs.org
-
Kenosha, Wisconsin, United States, 53142
- Recruiting
- Aurora Cancer Care-Kenosha South
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
La Crosse, Wisconsin, United States, 54601
- Recruiting
- Gundersen Lutheran Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 608-775-2385
- Email: cancerctr@gundersenhealth.org
-
Principal Investigator:
- Kurt Oettel
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Principal Investigator:
- Priyanka Pophali
-
Contact:
- Site Public Contact
- Phone Number: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Madison, Wisconsin, United States, 53718
- Recruiting
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Principal Investigator:
- Priyanka Pophali
-
Contact:
- Site Public Contact
- Phone Number: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
-
Marinette, Wisconsin, United States, 54143
- Recruiting
- Aurora Bay Area Medical Group-Marinette
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Marshfield, Wisconsin, United States, 54449
- Recruiting
- Marshfield Medical Center-Marshfield
-
Contact:
- Site Public Contact
- Phone Number: 800-782-8581
- Email: oncology.clinical.trials@marshfieldresearch.org
-
Principal Investigator:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Children's Hospital of Wisconsin
-
Contact:
- Site Public Contact
- Phone Number: 414-955-4727
- Email: MACCCTO@mcw.edu
-
Principal Investigator:
- Michael J. Burke
-
Milwaukee, Wisconsin, United States, 53209
- Recruiting
- Aurora Cancer Care-Milwaukee
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Milwaukee, Wisconsin, United States, 53215
- Recruiting
- Aurora Saint Luke's Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Milwaukee, Wisconsin, United States, 53233
- Recruiting
- Aurora Sinai Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Mukwonago, Wisconsin, United States, 53149
- Recruiting
- ProHealth D N Greenwald Center
-
Contact:
- Site Public Contact
- Email: research.institute@phci.org
-
Principal Investigator:
- Timothy R. Wassenaar
-
Oconomowoc, Wisconsin, United States, 53066
- Recruiting
- ProHealth Oconomowoc Memorial Hospital
-
Principal Investigator:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Phone Number: 262-928-7878
-
Oshkosh, Wisconsin, United States, 54904
- Recruiting
- Vince Lombardi Cancer Clinic - Oshkosh
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Racine, Wisconsin, United States, 53406
- Recruiting
- Aurora Cancer Care-Racine
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Sheboygan, Wisconsin, United States, 53081
- Recruiting
- Vince Lombardi Cancer Clinic-Sheboygan
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Sheboygan, Wisconsin, United States, 53081
- Recruiting
- Saint Vincent Hospital Cancer Center at Sheboygan
-
Principal Investigator:
- Catherine A. Long
-
Contact:
- Site Public Contact
- Phone Number: 920-433-8889
- Email: WI_research_admin@hshs.org
-
Sturgeon Bay, Wisconsin, United States, 54235-1495
- Recruiting
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Principal Investigator:
- Catherine A. Long
-
Contact:
- Site Public Contact
- Phone Number: 920-433-8889
- Email: WI_research_admin@hshs.org
-
Summit, Wisconsin, United States, 53066
- Recruiting
- Aurora Medical Center in Summit
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Two Rivers, Wisconsin, United States, 54241
- Recruiting
- Vince Lombardi Cancer Clinic-Two Rivers
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
Waukesha, Wisconsin, United States, 53188
- Recruiting
- UW Cancer Center at ProHealth Care
-
Principal Investigator:
- Timothy R. Wassenaar
-
Contact:
- Site Public Contact
- Phone Number: 262-928-5539
- Email: Chanda.miller@phci.org
-
Wauwatosa, Wisconsin, United States, 53226
- Recruiting
- Aurora Cancer Care-Milwaukee West
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
West Allis, Wisconsin, United States, 53227
- Recruiting
- Aurora West Allis Medical Center
-
Contact:
- Site Public Contact
- Phone Number: 414-302-2304
- Email: ncorp@aurora.org
-
Principal Investigator:
- Rebecca E. McFall
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be 5 to 60 years of age at the time of enrollment
- Patients with newly diagnosed untreated histologically confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS]) with stage I or II disease
- Patients must have bidimensionally measurable disease (at least one lesion with longest diameter >= 1.5 cm)
- Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained
Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease.
- Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality.
- Patients >= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2
- Patients =< 17 years of age must have a Lansky performance score of >= 50
Pediatric patients (age 5-17 years): A serum creatinine based on age/sex as follows (within 28 days prior to enrollment):
- 2 to < 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female)
- 6 to < 10 years (age): 1 mg/dL (male), 1 mg/dL (female)
- 10 to < 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female)
- 13 to < 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female)
- >= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine creatinine clearance >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment) OR a glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility
- For adult patients (age 18 years or older) (within 28 days prior to enrollment): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight
Total bilirubin =< 2 x upper limit of normal (ULN) (within 28 days prior to enrollment)
- Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
Aspartate aminotransferase (AST) =< 3 x ULN (within 28 days prior to enrollment)
- Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
Alanine aminotransferase (ALT) =< 3 x ULN (within 28 days prior to enrollment)
- Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
- Shortening fraction of >= 27% by echocardiogram (ECHO), multigated acquisition scan (MUGA), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of >= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment)
- Diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted value as corrected for hemoglobin by pulmonary function test (PFT) (within 28 days prior to enrollment). If unable to obtain PFTs, the criterion is: a pulse oximetry reading of > 92% on room air
- Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
- Patients with nodular lymphocyte predominant Hodgkin lymphoma
- Patients with a history of active interstitial pneumonitis or interstitial lung disease
- Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients
- Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, autoimmune conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills
Patients with a condition requiring systemic treatment with either corticosteroids (defined as equivalent to > 10 mg daily predniSONE for patients >= 18 years or > 0.5 mg/kg [up to 10 mg/day] for patients < 18 years) or other immunosuppressive medications within 14 days prior to enrollment
- Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=< 10 mg daily for patients >= 18 years or =< 0.5 mg/kg [up to 10 mg/day] predniSONE equivalents) are permitted in the absence of active autoimmune disease
- Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1
- Short term use of corticosteroids for premedication or treatment of an allergy or hypersensitivity is considered an acceptable use of corticosteroids.
- Patients with peripheral neuropathy > grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome
- Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
- Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL
- Prior solid organ transplant
- Prior allogeneic stem cell transplantation
- Live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette Guerin [BCG], oral polio vaccine, and oral typhoid). Administration of messenger ribonucleic acid (mRNA) vaccines are permitted
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test within 28 days prior to enrollment is required for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last treatment
Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method for the duration of their study drug therapy. Following therapy, patients will be advised to use contraception as per institutional practice or as listed below for investigational agents, whichever is longer
- Men and women of childbearing potential (WOCBP) must use effective contraception during the study and for 2 months for WOCBP and 4 months for men, after last dose of brentuximab vedotin
- WOCBP must continue contraception for a period of at least 5 months after the last dose of nivolumab
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm C (ABVD, eBEACOPP or eBPDac, ISRT)
See Detailed Description.
|
Given IV
Other Names:
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given PO
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given PO
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
Undergo ISRT
Other Names:
Given PO
Other Names:
|
|
Active Comparator: Arm A (ABVD)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER.
Patients then receive ABVD IV for an additional 2 cycles on study.
Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity.
Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
Patients may also undergo blood sample collection on trial.
|
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
|
|
Experimental: Arm B (ABVD, brentuximab vedotin, nivolumab)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER.
Patients then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle.
Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
Patients may also undergo blood sample collection on trial.
|
Given IV
Other Names:
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
|
|
Experimental: Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER.
Patients then receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT.
Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
Patients may also undergo blood sample collection on trial.
|
Given IV
Other Names:
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
Undergo ISRT
Other Names:
|
|
Experimental: Arm E (ABVD, AVD)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER.
Patients then receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
Patients may also undergo blood sample collection on trial.
|
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
|
|
Experimental: Arm F (ABVD, brentuximab vedotin, nivolumab)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER.
Patients then receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial.
Patients may also undergo blood sample collection on trial.
|
Given IV
Other Names:
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
|
|
Experimental: Arm G (ABVD, eBEACOPP or eBPDac, ISRT)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER.
Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C.
|
Given IV
Other Names:
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given PO
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given PO
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
Undergo ISRT
Other Names:
Given PO
Other Names:
|
|
Experimental: Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)
Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle.
Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER.
Patients then receive treatment and imaging, and may undergo blood sample collection as in arm D.
|
Given IV
Other Names:
Ancillary studies
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo CT and/or PET-CT
Other Names:
Given IV
Other Names:
Undergo FDG-PET
Other Names:
Undergo MRI and/or PET-MRI
Other Names:
Undergo FDG-PET, PET, PET-CT, and/or PET-MRI
Other Names:
Undergo ISRT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival (PFS) in rapid early responder (RER) patients
Time Frame: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
|
Will compare the PFS of RER patients randomized to immunotherapy (IO) therapy (brentuximab vedotin-nivolumab) against those randomized to standard therapy.
PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.
|
From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first
|
|
PFS in slow-early responder (SER) patients
Time Frame: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first
|
Will compare PFS among SER patients randomized to IO therapy and involved-site radiation therapy against arms containing standard therapy.
PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.
|
From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of self-reported late morbidities
Time Frame: Assessed up to 12 years from last enrollment
|
Will be collected by using validated measures from the St. Jude Life Cohort.
The cumulative incidence of late-morbidities (e.g., cardiovascular, pulmonary and endocrine) will be compared between the standard chemotherapy and the IO therapy and among different age groups (7-14; 15-40 and 41-60) with K-sample method.
The frequencies of selected organ toxicities will be compared between two treatment arms, among the three age groups and between RT and non-RT with chi-square tests.
|
Assessed up to 12 years from last enrollment
|
|
Effect of metabolic tumor burden (MTV) on PFS
Time Frame: At baseline prior to initiation of therapy
|
MTV will be measured at baseline using fludeoxyglucose F-18 (FDG)-PET.
The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.
|
At baseline prior to initiation of therapy
|
|
Effect of total lesion glycolysis (TLG) on PFS
Time Frame: At baseline prior to initiation of therapy
|
TLG will be measured at baseline using FDG-PET.
The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.
|
At baseline prior to initiation of therapy
|
|
Overall survival (OS) in RER patients
Time Frame: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
The non-inferiority of IO therapy to standard therapy will be tested in the randomized and eligible RER cohort using a confidence interval approach performed 12 years after the last patient not lost to follow-up has reached more than 12 years of follow-up (patients are followed up to 13 years).
|
Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
|
OS in SER patients
Time Frame: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
Will be compared between a standard chemotherapy approach and an IO therapy approach among the SER patients.
|
Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment
|
|
OS for entire patient population
Time Frame: Time from randomization to death due to any cause, assessed at 12 years after the last enrollment
|
Will be based on a confidence interval approach conducted after the last patient not lost to follow-up has been followed for at least 12 years from randomization.
Twelve-year OS and its corresponding 90% confidence interval will be estimated with the Kaplan-Meier method for each study arm within the entire randomized and evaluable trial population.
|
Time from randomization to death due to any cause, assessed at 12 years after the last enrollment
|
|
PFS for favorable risk patients
Time Frame: Up to 12 years
|
Will be estimated in patients with favorable features at diagnosis.
PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach.
PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.
|
Up to 12 years
|
|
PFS for unfavorable risk patients
Time Frame: Up to 12 years
|
Will be estimated in patients with unfavorable features at diagnosis.
PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach.
PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.
|
Up to 12 years
|
|
PFS for entire population
Time Frame: Up to 12 years
|
PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach.
PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.
|
Up to 12 years
|
|
Incidence of adverse events (AEs)
Time Frame: Assessed up to 12 years from last enrollment
|
Will use the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer guidelines to capture immune-related AEs.
Physician-reported treatment related AEs will be reported for all grades using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Rates of individual toxicities with grades greater or equal to 3 will be compared between the pooled IO and standard arms using exact binomial tests.
The maximum grade for each toxicity will be recorded for each patient.
The rates and confidence intervals for these toxicities will be provided.
Comparison of AEs will also be conducted for physician-reported treatment-related AEs between RT and non-RT patients.
|
Assessed up to 12 years from last enrollment
|
|
Patient reported outcomes (PRO)-CTCAE
Time Frame: Assessed up to 12 years from last enrollment
|
Targeted patient-reported AEs will be collected at each time point using the PRO-CTCAE for patients 7 years and older.
For youth (7-17 years) the Pediatric PRO-CTCAE form will be used and for those 18 years and older adult the PRO-CTCAE form will be used.
For information collected by each of the above forms, the scores for each attribute together with frequency, severity and/or interference will be presented descriptively using summary statistics at each assessment time.
Additionally, the worst severity and/or interference over the entire course will be summarized.
The changes among main time points will be calculated.
The results will be provided for the whole population and compared between subpopulations by arms and by age groups.
Regression models based on longitudinal measurements can be constructed by considering the following covariates besides age groups: baseline demographics, clinical risk factors, and study arms.
|
Assessed up to 12 years from last enrollment
|
|
Patient-reported cognitive deficits
Time Frame: Baseline up to 1 year from end of study treatment
|
Will be measured by validated short forms from the Neuro-QoL initiative.
Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population.
The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure.
To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values.
Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.
|
Baseline up to 1 year from end of study treatment
|
|
Patient-reported health-related quality of life
Time Frame: Baseline up to 1 year from end of study treatment
|
Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population.
The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure.
To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values.
Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.
|
Baseline up to 1 year from end of study treatment
|
|
Contribution of SDOH to PFS by race and ethnicity
Time Frame: Assessed up to 12 years after last enrollment
|
Kaplan-Meier (K-M) curves of PFS will be generated by racial/ethnic groups (e.g., non-Hispanic white [NHW], non-Hispanic black [NHB], Hispanic).
The p values for the K-M curve comparison will be obtained from log-rank tests.
Associations between race/ethnicity and PFS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO).
Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models.
|
Assessed up to 12 years after last enrollment
|
|
Contribution of SDOH to OS by race and ethnicity
Time Frame: Assessed up to 12 years after last enrollment
|
K-M curves of OS will be generated by racial/ethnic groups (e.g., NHW, NHB, Hispanic).
The p values for the K-M curve comparison will be obtained from log-rank tests.
Associations between race/ethnicity and OS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO).
Backward selection will be used to select those factors with p-value < 0.2, which will be included in final multivariable models.
|
Assessed up to 12 years after last enrollment
|
|
Event-free survival (EFS)
Time Frame: Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment
|
Pooling IO treatment arms and standard treatment arms, EFS and corresponding confidence intervals will be estimated with the Kaplan-Meier approach for patients assigned versus (vs.) not assigned to receive radiaton therapy (RT), and compared using the log-rank test.
|
Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment
|
|
Patient-reported fatigue
Time Frame: Baseline up to 1 year from end of study treatment
|
Will be measured by validated short forms from the Patient Reported Outcomes Measurement Information System initiatives.
Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population.
The minimal clinically important difference (MCID) in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure.
To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values.
Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.
|
Baseline up to 1 year from end of study treatment
|
|
Contribution of social determinants of health (SDOH) to PET2 response by race and ethnicity
Time Frame: After Cycle 2 of treatment (1 cycle = 28 days)
|
PET2 Response will be compared by race and ethnicity using Fisher exact tests.
|
After Cycle 2 of treatment (1 cycle = 28 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Association between FDG PET parameters obtained by automated measurements and PFS
Time Frame: At baseline, post cycle 2, and at the end of therapy
|
The association between FDG PET parameters obtained by automated measurements using convolutional neural networks and PFS will be evaluated in this aim.
The PET parameters of interest are total MTV and TLG, tumor standardized uptake value change.
PET parameters will be obtained based on artificial intelligence (AI) based measurements.
The effect of these PET measurements will be evaluated by Cox regression models.
|
At baseline, post cycle 2, and at the end of therapy
|
|
Agreement between AI derived FDG-PET measurement extraction and physician-based manual quantitative PET measurement
Time Frame: At baseline, post cycle 2, and at the end of therapy
|
Will compare AI derived automated quantitative FDG-PET measurement extraction and physician-based manual quantitative PET measurement with Spearman rank correlation coefficients for each extracted PET metric.
|
At baseline, post cycle 2, and at the end of therapy
|
|
Completion rate of PRO and health-related quality of life contact forms
Time Frame: At 1 year off treatment
|
Will be evaluated for the first 450 eligible participants.
|
At 1 year off treatment
|
|
PFS comparison between treatment arms for each age group
Time Frame: Up to 12 years
|
Will be compared between a standard chemotherapy approach and an IO therapy approach within different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years) using log-rank tests.
Cox regression models will be constructed to evaluate the treatment effects for different age groups while considering the impact of other potentially prognostic variables including baseline demographics and clinical risk factors.
PFS and corresponding confidence intervals for each age group will be estimated with the Kaplan-Meier method, overall and by treatment arms.
In additional models, age may be evaluated as a continuous variable with potentially non-linear effects on PFS.
|
Up to 12 years
|
|
Incidence of patient reported adverse events and provider adverse event reporting
Time Frame: Assessed up to 12 years
|
Will be collected by PRO-CTCAE and Ped-PRO-CTCAE.
The patient reported AEs will be compared to provider reported AEs reported descriptively.
|
Assessed up to 12 years
|
|
Association between self-reported race/ethnicity and dimensional SDOH
Time Frame: Assessed up to 12 years
|
Will be evaluated by Chi-square tests or Fisher exact tests for sparse data.
Will also calculate the area deprivation index (derived from patient-reported address and zip code to census block-group data for patients treated in the United States, and the Canadian Index of Multiple Deprivation for patients treated in Canada) and investigate its association with race/ethnicity and SDOH.
|
Assessed up to 12 years
|
|
Post-relapse/post-progression OS by race/ethnicity and select SDOH measures
Time Frame: Assessed up to 12 years
|
The K-M curves will be presented together with p-values via log-rank tests across the different race/ethnicity groups for each treatment arm.
Cox proportional hazard models to evaluate the relationship between race/ethnicity and post-relapse OS will be constructed.
|
Assessed up to 12 years
|
|
Concordance and discordance of 5-point score (PS) visual PET assessments
Time Frame: At baseline, post cycle 2, and at end of systemic therapy
|
The concordance and discordance of 5-PS visual PET assessment from rapid central review and local institutional review will be evaluated at each of the timepoints.
Will collect and retrospectively review local vs.
central review concordance rates.
For discordant cases, will document the differences in treatments if only local review or only central review were performed
|
At baseline, post cycle 2, and at end of systemic therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kara M Kelly, Roswell Park Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Lymphoma
- Hodgkin Disease
- Peptides
- Amino Acids, Peptides, and Proteins
- Oligopeptides
- Proteins
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Investigative Techniques
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Azoles
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carbohydrates
- Carboxylic Acids
- Alkaloids
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glucosides
- Glycosides
- Triazenes
- Imidazoles
- Amides
- Indoles
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Benzene Derivatives
- Chemistry Techniques, Analytical
- Spectrum Analysis
- Phosphoramide Mustards
- Nitrogen Mustard Compounds
- Mustard Compounds
- Hydrocarbons, Halogenated
- Phosphoramides
- Organophosphorus Compounds
- Pregnadienetriols
- Pregnadienediols
- Vinca Alkaloids
- Secologanin Tryptamine Alkaloids
- Indole Alkaloids
- Indolizidines
- Indolizines
- Anthracyclines
- Naphthacenes
- Aminoglycosides
- Glycoconjugates
- Deoxyglucose
- Deoxy Sugars
- Daunorubicin
- Acids, Carbocyclic
- Glycopeptides
- Benzoates
- Benzamides
- Nivolumab
- Brentuximab Vedotin
- Fluorodeoxyglucose F18
- Prednisone
- Prednisolone
- Cyclophosphamide
- Etoposide
- Doxorubicin
- Vincristine
- Dacarbazine
- Methylprednisolone
- Vinblastine
- Bleomycin
- Procarbazine
- Specimen Handling
- Magnetic Resonance Spectroscopy
- deltacortene
- prednylidene
- etoposide phosphate
Other Study ID Numbers
- NCI-2022-10845 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA180886 (U.S. NIH Grant/Contract)
- AHOD2131 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.